Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Takeda Cambridge Ltd.

Division of Takeda Pharmaceutical Co. Ltd.
www.paradigm-therapeutics.com

Latest From Takeda Cambridge Ltd.

Takeda’s Strategic Run Up To Nycomed

With the acquisition of Nycomed, Takeda’s long-standing strategy for becoming a world-class pharma has come into focus. The company spent much of the past decade building up its pipeline, globalizing R&D and importing Western staff, assets, platforms and processes. It also began a hectic period of M&A unparalleled among Japanese companies, culminating in 2011 with its acquisition of Nycomed. Now its focus will need to shift from big acquisitions and organizational makeover to execution.

BioPharmaceutical Business Strategies

Big Partnerships Give Biotechs A Boost To Richer Exits

Biotechs in recent years are more likely to fetch a higher acquisition price – practically the only way for investors to exit these days – if the company has previously signed a major alliance. But the partners aren't necessarily the ones buying.

BioPharmaceutical Deals

Takeda's Global Ambition

Takeda Pharmaceutical's drug business started out manufacturing and selling bismuth-the basic ingredient in Pepto-Bismol--in 1895. A century later, it's still chained to the stomach-settling game with Prevacid, a $1.4 billion drug whose patent will expire in 2009, taking with it a huge percentage of Takeda's earnings. That's one big reason why Japan's largest and most international pharmaceutical company is on a US-focused dealmaking tear. Since February, Takeda has inked three major licensing partnerships and completed the largest acquisition in its history in a desperate attempt to shore up a thin pipeline.

Deals Shaping the Medical Industry (4/07)

The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Paradigm Therapeutics Ltd.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Takeda Pharmaceutical Co. Ltd.
  • Senior Management
  • Alastair Riddell, CEO
    Jim Sutcliffe, Mgr., Fin.
    Ian Gray, Head, Research
  • Contact Info
  • Takeda Cambridge Ltd.
    Phone: (44) 1223 477910
    418 Cambridge Science Pk.
    Milton Rd.
    Cambridge, CB4 0PA
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register